Incyte: Undervalued And Expecting FDA Feedback In H2 2021
valiantsin suprunovich/iStock via Getty Images
In 2021, Incyte Corporation (NASDAQ:INCY) expects free cash flow growth as well as many updates from the FDA. With the cash flow from operations growing in the last quarters, Incyte Corporation appears undervalued….
